Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05601011
Other study ID # RS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 31, 2022
Est. completion date October 19, 2023

Study information

Verified date October 2022
Source Peking University Third Hospital
Contact Hong Qi, M.D.
Phone 13901066889
Email doctorqihong@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

to analyze the clinical and tear molecular profile up to 6 months after FS-LASIK surgery


Description:

FS-LASIK is a refractive surgery technique widely used in China. To explore the role of inflammation and nerve in the occurrence and development of dry eyes after FS-LASIK by dynamically observing the ocular surface characteristics and the levels of inflammatory factors and neurotransmitters in the early and late stage after FS-LASIK.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 19, 2023
Est. primary completion date October 19, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Patients who preparing for FS-LASIK with age between 18 and 45 years old 2. Any gender 3. Provision of written informed consent. Exclusion Criteria: 1. active ocular infection, ocular inflammation, active ocular allergy, severe blepharitis or obvious inflammation of the eyelid margin. 2. Pregnant and lactating women, or those planning a pregnancy over the course of the study 3. Uncontrolled systemic disease 4. Suffer from diseases that may affect corneal nerves, such as keratoconus, trigeminal neuralgia, allergic conjunctivitis, etc.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Peking University Third Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary ocular surface disease index (OSDI) OSDI is one of the most frequently used questionnaires for evaluation of dry eye disease (DED). This includes 12 questions which measure the frequency of symptoms over the recent week, and the scores range from 0 to 100. from Pre-surgery to 6 months after surgery
Primary Tear break-up time (TBUT)(s) BUT is the time from normal blinking to the first appearance of a break in the tear film. from Pre-surgery to 6 months after surgery
Primary Corneal fluorescein staining (CFS) The degree of fluorescein staining of the cornea was evaluated using the National Eye Institute (NEI) scale of five corneal regions (central, superior, temporal, nasal, and inferior). The scores range from 0 to 15. from Pre-surgery to 6 months after surgery
Primary Schirmer ? test (S?t) (mm/5 minutes) The Schirmer I test is performed using sterile strips without anesthesia. The strips are placed in the lateral part of the inferior fornix of the eye for 5min and the extent of tear flow down was measured in millimeters. from Pre-surgery to 6 months after surgery
Secondary the concentration of Interleukin-1ß(IL-1ß) (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-1ß levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of Interleukin-6 (IL-6) (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-6 levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of Interleukin-10 (IL-10) (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-10 levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of Interleukin-23 (IL-23) (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-23 levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of Interleukin-17A (IL-17A) (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-17A levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of tumor necrosis factor-a (TNF-a)(pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. TNF-a levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of interferon-? (IFN-?)(pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IFN-? levels will be quantified by Luminex immunoassay from Pre-surgery to 6 months after surgery
Secondary the concentration of granulocyte-macrophage colony-stimulating factor (GM-CSF)(pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. GM-CSF levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of substance P (SP)(pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. SP levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of alpha-melanocyte-stimulating hormone (a-MSH) (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. a-MSH levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of ß-endorphin (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. ß-endorphin levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of neurotensin (pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. ß-endorphin levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary the concentration of oxytocin(pg/ml) basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. oxytocin levels will be quantified by Luminex immunoassay. from Pre-surgery to 6 months after surgery
Secondary Lissamine green staining To grade the temporal zone, the subject looks nasally; to grade the nasal zone the subject looks temporally. The upper and lower conjunctiva can also be graded. from Pre-surgery to 6 months after surgery
Secondary meibomian gland dropout rate grade 0: no gland atrophy; grade 1: =1/3 gland atrophy; grade 2: 1/3 to 2/3 gland atrophy;grade 3: >2/3 gland atrophy. from Pre-surgery to 6 months after surgery
Secondary corneal sensitivity (range, 60-0 mm) Corneal sensitivity will be measured in the right eye only using the Cochet-Bonnet aesthesiometer and the ascending method of limits to determine the threshold of stimulus detection. from Pre-surgery to 6 months after surgery
Secondary sub-basal corneal nerve density (mm/mm2) Sub-basal corneal nerve plexus image will be acquired using a laser scanning confocal microscope. from Pre-surgery to 6 months after surgery
Secondary numerical rating scale (NRS) The NRS was used to evaluate ocular pain and consists of a numbered line from 0 to 10 scores that measures pain intensity: 0-1: no pain; 2-4: mild pain; 5-7: moderate pain; and 8-10: severe pain. from Pre-surgery to 6 months after surgery
Secondary NPSI-Eye (range 0-100 score) Neuropathic Pain Symptom Inventory modified for the Eye (NPSI-Eye) (range 0-100 over a 24-hour recall period) from Pre-surgery to 6 months after surgery
See also
  Status Clinical Trial Phase
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A